In the PREVENT-19 phase 3 trial of the NVX-CoV2373 vaccine (NCT04611802), anti-spike
binding IgG concentration (spike IgG), anti-RBD binding IgG concentration (RBD IgG), and …

Background Protection afforded from prior disease among patients with coronavirus disease
2019 (COVID-19) infection is unknown. If infection provides substantial long-lasting …

An increasing proportion of the population has acquired immunity through COVID-19
vaccination and previous SARS-CoV-2 infection, ie, hybrid immunity, possibly affecting the …

Patients with hematologic malignancies have an increased risk of severe COVID‐19
infection. Vaccination against COVID‐19 is especially important in these patients, but …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread
worldwide as a severe pandemic. Although its seroprevalence is highly variable among …

Background Waning of protection against infection with severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) conferred by 2 doses of the BNT162b2 vaccine begins shortly …

Dermatologists diagnose and treat many immune-mediated inflammatory diseases (IMID).
Understanding the inherent immune dysregulation of these diseases as well as the …

How will the coronavirus disease 2019 (COVID-19) pandemic develop in the coming months
and years? Based on an expert survey, we examine key aspects that are likely to influence …

Background A correlate of protection (CoP) is an immunological marker associated with
protection against infection. Despite an urgent need, a CoP for SARS-CoV-2 is currently …

COVID-19 natural immunity Page 1 -1- COVID-19 natural immunity Scientific brief 10 May 2021
Key Messages: • Within 4 weeks following infection, 90-99% of individuals infected with the …